Shuji Murakami

15.3k total citations · 1 hit paper
172 papers, 3.0k citations indexed

About

Shuji Murakami is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, Shuji Murakami has authored 172 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 81 papers in Oncology and 32 papers in Electrical and Electronic Engineering. Recurrent topics in Shuji Murakami's work include Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Diagnosis and Treatment (43 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Shuji Murakami is often cited by papers focused on Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Diagnosis and Treatment (43 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Shuji Murakami collaborates with scholars based in Japan, United States and Australia. Shuji Murakami's co-authors include Emiko Senba, Hiroki Imbe, Chiharu Kubo, Yoshihiro Morikawa, Haruhiro Saito, Hiroyuki Ito, Haruhiko Nakayama, Tetsuro Kondo, Tomoyuki Yokose and Rina Hui and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Shuji Murakami

161 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019 305 citations Shuji Murakami et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shuji Murakami Japan	28	1.4k	1.1k	386	380	318	172	3.0k
Ari Green United States	38	203 0.1×	667 0.6×	184 0.5×	1.5k 3.8×	606 1.9×	111	6.4k
Partha Dutta United States	26	291 0.2×	237 0.2×	121 0.3×	1.1k 2.8×	133 0.4×	65	3.3k
Benjamin F. Cox United Kingdom	16	179 0.1×	269 0.2×	103 0.3×	212 0.6×	115 0.4×	49	1.8k
Volkmar Hans Germany	37	419 0.3×	235 0.2×	64 0.2×	1.5k 3.9×	92 0.3×	78	4.0k
Fumiaki Sato Japan	27	265 0.2×	246 0.2×	111 0.3×	856 2.3×	119 0.4×	140	2.4k
Jakob Matschke Germany	31	425 0.3×	475 0.4×	45 0.1×	1.1k 2.8×	196 0.6×	140	3.2k
Eran Sharon Israel	19	100 0.1×	310 0.3×	364 0.9×	170 0.4×	143 0.4×	60	1.5k
Clemens Warnke Germany	28	176 0.1×	593 0.6×	238 0.6×	276 0.7×	110 0.3×	117	2.2k
Makoto Nakagawa Japan	26	548 0.4×	600 0.6×	44 0.1×	500 1.3×	369 1.2×	177	2.6k
Koji Obata Japan	30	168 0.1×	162 0.2×	546 1.4×	633 1.7×	161 0.5×	118	2.8k

Countries citing papers authored by Shuji Murakami

Since Specialization

Citations

This map shows the geographic impact of Shuji Murakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuji Murakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuji Murakami more than expected).

Fields of papers citing papers by Shuji Murakami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuji Murakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuji Murakami. The network helps show where Shuji Murakami may publish in the future.

Co-authorship network of co-authors of Shuji Murakami

This figure shows the co-authorship network connecting the top 25 collaborators of Shuji Murakami. A scholar is included among the top collaborators of Shuji Murakami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuji Murakami. Shuji Murakami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wei, Feifei, Hiroyuki Takeda, Koichi Azuma, et al.. (2025). Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors. Frontiers in Immunology. 16. 1666030–1666030.

Cuppens, Kristof, K. Papadopoulos, Makoto Nishio, et al.. (2025). 8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Open. 10. 104164–104164. 1 indexed citations

Murakami, Shuji, et al.. (2024). Photocatalytic Denitrative Alkenylation of Nitroalkanes. Organic Letters. 26(48). 10218–10223. 4 indexed citations

Ohe, Yuichiro, Satoshi Watanabe, Xiubao Ren, et al.. (2024). BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. 42(16_suppl). 8001–8001. 15 indexed citations

Nishio, Makoto, Shuji Murakami, Hisato Kawakami, et al.. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. 4(1). 226–235. 2 indexed citations

Nakamichi, Shinji, Kaoru Kubota, Toshihiro Misumi, et al.. (2024). Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study). Clinical Cancer Research. 30(6). 1104–1110. 8 indexed citations

Murakami, Shuji, et al.. (2023). Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review. Thoracic Cancer. 14(28). 2886–2889. 1 indexed citations

Murakami, Shuji, et al.. (2023). Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. OncoTargets and Therapy. Volume 16. 99–108. 5 indexed citations

Kondo, Tetsuro, Kaoru Kubota, Shinji Nakamichi, et al.. (2023). 1294P A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study). Annals of Oncology. 34. S746–S747. 1 indexed citations

10.

Fang, Jian, et al.. (2023). OFDM Signal Transmission Using Distributed Fiber-Optic Acoustic Sensing. 1–2. 1 indexed citations

11.

Horinouchi, Hidehito, Aya Kuchiba, Yuji Matsumoto, et al.. (2022). Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. Journal of Cancer Research and Clinical Oncology. 149(7). 3185–3191. 1 indexed citations

12.

Shibaki, Ryota, Tatsuya Yoshida, Shuji Murakami, et al.. (2022). Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. Clinical Lung Cancer. 23(6). 477–486. 13 indexed citations

13.

Murakami, Shuji, Ryota Shibaki, Yuji Matsumoto, et al.. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody. Thoracic Cancer. 11(12). 3585–3595. 36 indexed citations

14.

Horinouchi, Hidehito, Yuji Matsumoto, Shuji Murakami, et al.. (2019). Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer. Thoracic Cancer. 10(5). 1141–1148. 7 indexed citations

15.

Shinno, Yuki, Yasushi Goto, Sho Watanabe, et al.. (2018). Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open. 3(7). e000399–e000399. 5 indexed citations

16.

Murakami, Shuji, Haruhiro Saito, Tetsuro Kondo, et al.. (2013). 18F-fluorodeoxyglucose uptake on positron emission tomography in mucinous adenocarcinoma. European Journal of Radiology. 82(11). e721–e725. 13 indexed citations

17.

Murakami, Shuji, et al.. (2011). Lung Cancer Associated with Remitting Seronegative Symmetrical Synovitis with Pitting Edema-like Features. Haigan. 51(4). 253–258. 5 indexed citations

18.

Fukushima, Shogo, et al.. (2001). Light weight glasses for measuring pupil and eye movement equipped with display function. 101(109). 75–78. 1 indexed citations

19.

Nozaki, Takehiro, et al.. (2000). The Relation between the Ratio of Neutrophils to Lymphocytes in Leukocytes and the Function of the Autonomic Nervous System in Patients with Anorexia Nervosa. 40(8). 611–616. 2 indexed citations

20.

Murakami, Shuji, et al.. (1971). Adaptive Feedback Communication System in a Fading Environment. Kobe University Repository Kernel (Kobe University). 17. 127–147. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact